Gentian Diagnostics appoints Dr Hilja Ibert as CEO | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
16323
post-template-default,single,single-post,postid-16323,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

Gentian Diagnostics appoints Dr Hilja Ibert as CEO

Gentian Diagnostics appoints Dr Hilja Ibert as CEO

Moss, July 16, 2018

Gentian Diagnostics (OSE: GENT-ME) is pleased to announce the appointment of Dr Hilja Ibert as new Chief Executive Officer. Dr Ibert brings more than 25 years’ experience from the international diagnostic industry, and an extensive and strong leadership experience.

Dr Ibert has previously held the position as Vice President International Diagnostic Solutions at Hologic, as well as several senior positions within Becton Dickinson and bioMerieux within the field of diagnostics. She holds a PhD degree in Nutrition Science from the University of Bonn, Germany.

Ms Ibert also has experience with early stage R&D companies, lastly in her position as Chief Executive Officer for miDiagnostics in Belgium. Ms Ibert will take up the responsibility as the CEO of Gentian Diagnostics effective from 16 July 2018.

Tomas Settevik, Chairman of Gentian Diagnostics Board of Directors, said: “I am very pleased that Gentian has managed to attract a very talented and experienced CEO to take the helm of Gentian Diagnostics. Dr Hilja Ibert has the required skills within all areas that are of key importance for the future success of Gentian, and she will enable for the Gentian team to realize the significant potential that resides within both the in-market products and the pipeline products”.

“I would also like to extend a very large appreciation of the strong efforts- and performance of our existing CEO, Bård Sundrehagen. He has done a fantastic job through being extremely dedicated in his role for Gentian. His resilience over the past years has ensured that we have a strong foundation whereby to continue to build an even stronger company. We are extremely pleased that Mr Sundrehagen will continue to play an important part in the future of Gentian, as he has accepted to continue in the capacity of Executive Vice President Business Development”.

Hilja Ibert added: “I very much look forward to become a part of the highly talented Gentian team, a team which has proven its expertise to develop and commercialize product solutions for the clinical diagnostics market. Together, we will support healthcare providers from all over the world to improve patient outcome and laboratory efficiency and by doing so, creating a great future for Gentian.

For further information, please contact: Tomas Settevik, Chairman Cell: +47 90 79 48 25

 

MeldingsID: 455659

UtstederID: GENT-ME

Instrument: GENT-ME

Marked: Merkur Market

Kategori: ANNEN INFORMASJONSPLIKTIG REGULATORISK INFORMASJON

Informasjonspliktige opplysninger: Ja

 

Vedlegg: CEO_July12_2018_Announcement (1)